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Overexpression of multidrug resistance proteins P-glycoprotein (P-gp, MDR1) causes resistance of the tumor cells against
a variety of chemotherapeutic agents. 3-(1-methyl-1H-indol-3-yl)-1-phenyl-4-(1-(3-(piperidin-1-yl)propyl)-1H-pyrazolo[3,4-
b]pyridine-3-yl)-1H-pyrrole-2,5-dione (YQ36) is a novel analogue of bisindolylmaleimide, which has been reported to overcome
multidrug resistance. Here, we dedicated to investigate the anticancer activity of YQ36 on KB/VCR cells. The results revealed
that YQ36 exhibited great antiproliferative activity on three parental cell lines and MDR1 overexpressed cell lines. Moreover, the
hypersensitivity of YQ36 was conﬁrmed on the base of great apoptosis induction and unaltered intracellular drug accumulation
in KB/VCR cells. Further results suggested that YQ36 could not be considered as a substrate of P-gp, which contributed to
its successfully escaping from the eﬄux mediated by P-gp. Interestingly, we observed that YQ36 could accumulate in nucleus
and induce DNA damage. YQ36 could also induce the activation of caspase-3, imposing eﬀects on the mitochondrial function.
Collectively, our data demonstrated that YQ36 exhibited potent activities against MDR cells, inducing DNA damage and triggering
subsequent apoptosis via mitochondrial pathway.
Copyright © 2009 Ji Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
A major obstacle in cancer treatment is the resistance to
chemotherapeutic drugs. Frequently, tumor cells exhibit
resistance not only against a single class of drugs but also
against a variety of chemotherapeutics, such as vincristine,
doxorubicin, daunorubicin, taxol, and VP-16 [1, 2]. This
phenomenon, known as multidrug resistance (MDR), is
generally caused by three major mechanisms in cells [3]:
ﬁrst, decreased uptake of water-soluble drugs such as
folateantagonists,nucleosideanalogues,andcisplatin,which
require transporters to enter cells; second, various changes
in cells aﬀect the capacity of cytotoxic drugs to kill cells,
including alterations in cell cycle, increased repair of DNA
damage, reduced apoptosis and altered metabolism of drugs;
andthird,increasedenergy-dependenteﬄuxofhydrophobic
drugs that can easily enter the cells by diﬀusion through the
plasma membrane.
Of these mechanisms, one that is the most commonly
encountered in laboratory is the increased eﬄux of a broad
class of hydrophobic cytotoxic drugs that is mediated by one
ofafamilyofenergy-dependenttransporters,knownasATP-
binding cassette (ABC) transporters. The best-characterized
ABC transporter is the P-glycoprotein (P-gp), which is
encoded by the multidrug resistance gene 1 (MDR1 or
ABCB1) [3].
Itisreportedthatreversiblephosphorylationisapossible
mechanismforregulatingthetransportandchloridechannel
regulation functions of P-gp whereas protein kinase C (PKC)
is a good candidate for inducing such phosphorylation [4].
Therefore, inhibition of PKC is regarded as an approach
for overcoming MDR in cancer chemotherapy. Bisindolyl-
maleimide (BIM) was reported to exhibit remarkable PKC
inhibition [5]. However, little evidence showed that BIM
reversed MDR in cancer cells through inhibiting PKC
activity. In addition, most BIM analogues reversed MDR
via interacting with P-gp directly. Importantly, these results
could not support the concept of a major contribution of
PKC to a P-gp-associated MDR [6, 7].2 Journal of Biomedicine and Biotechnology
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Figure 1: The structure of YQ36.
In human cells, both the normal metabolic activities and
the environmental factors including UV light, γ-radiation,
and chemotherapeutic agents like mitomycin C could cause
DNA damage [8]. There are many types of damage to DNA
due to exogenous agents or endogenous cellular processes,
mainly including base loss, base modiﬁcation, replication
errors, inter-strand crosslinks, DNA-protein crosslinks, and
strand breaks. The p53 tumor suppressor protein plays a
major role in cellular response to DNA damage and other
genomic aberrations. Activation of p53 can lead to either cell
cycle arrest and DNA repair or apoptosis. Extensive studies
reveal that p53 can be phosphorylated by ATM, ATR, and
DNA-PK and the phosphorylation of p53 promotes both the
the accumulation of damaged DNA and the activation in
response to DNA damage [9].
Here, the newly designed and synthesized BIM analogue,
3-(1-methyl-1H-indol-3-yl)-1-phenyl-4-(1-(3-(piperidin-1-
yl)propyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1H-pyrrole-
2,5-dione (YQ36, Figure 1), exhibited obvious anti-MDR
eﬀect on a panel of cell lines with or without MDR1 expres-
sion. We demonstrated that YQ36 did not change P-gp pro-
teinexpressionoraﬀectedP-gpactivityasnoalterationofthe
phosphorylation status of P-gp was observed. Moreover, our
results indicated that YQ36 might not be a substrate of P-gp.
Interestingly, our experiments further suggested that YQ36
could accumulated in the nucleus and induce DNA damage
without poisoning topoisomerase II or inducing cross link
of DNA. In addition, YQ36 also induced the activation of
caspase-3 and inﬂuenced the expression of mitochondrial
pathway. These results showed that YQ36 was a potent agent
against MDR cells and DNA damage and mitochondrial
pathway might be involved in YQ36-induced apoptosis.
2.MaterialsandMethods
2.1. Drugs and Chemicals. YQ36 and BIM, a generous gift
from Professor Hu (ZJU-ENS Joint Laboratory of Medicinal
Chemistry, School of Pharmaceutical Sciences, Zhejiang
University), were synthesized as a recent published article
(“Synthesis and evaluation of novel 7-azaindazolyl-indolyl-
maleimidederivativesasantitumoragentsandproteinkinase
C inhibitors”: Q. Ye et al. Bioorg. Med. Chem. 2009. in
press). YQ36 and BIM were dissolved in DMSO (10.0mM
stock solution) and stored at −20
◦C. Doxorubicin (DOX)
was purchased from Sigma (St Louis, MO, USA). Stock
solution of DOX (10mM) was prepared in DMSO and
stored at −20
◦C. The primary antibodies to caspase-9,
caspase-3, Bcl-2, Bax, p53, p-p53, Apaf-1, Akt, p-Akt, p-Jnk,
HSP60 and β-Actin, and HRP-labeled secondary antigoat,
antimouse, and antirabbit antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Appropriate
antibodies to cleaved caspase-3, Smac and XIAP from Cell
Signaling Technology (Beverly, MA) and P-gp from Merck
(Darmstadt, Germany) were also used. ECL, a western blot
detection reagent, was purchased from Pierce Biotechnology
(Rockford, IL). The caspase inhibitor BOC-D-FMK and
Z-DEVD-FMK were purchased from Merck (Darmstadt,
Germany) and were dissolved in DMSO (100.0mM and
40.0mM stock solution resp.).
2.2. Fluorescence Microscope. Cells were cultured in 6-
well plates. After treated with YQ36 (40μM) for 1 hour,
samples were examined in a ﬂuorescence microscope and
photographed using a Digital Color Camera DFC 300FX
(Leica, Germany).
2.3.CellLines. KB,KB/VCR,K562,andK562/ADRcellswere
maintained in RPMI 1640 (Gibco, 2g/l glucose) and MCF-
7, and MCF-7/DOR were maintained in HG-Dulbecco’s
modiﬁed Eagle’s medium (Gibco, 4.5g/L glucose); both
media were supplemented with 10% heat-inactivated new-
born calf serum (NCS, Gibco) plus 100U/mL penicillin. All
of the cell lines were purchased from the Institute of Cell
Biology (Shanghai, PRC) and grown at 37
◦Ci na5 %C O 2
atmosphere.
2.4. Antiproliferation Assay. Cells were cultured in 96-
well plates and the Antiproliferation activity of YQ36 and
doxorubicin on KB and KB/VCR cells were detected using
the MTT assay. After treatment in 96-well plates, MTT
solution (5.0mg/mL in RPMI-1640, Sigma, St. Louis, MO)
was added (20.0μL/well), and the plates were incubated
for an additional 4 hours at 37
◦C. The purple formazan
crystals were dissolved in 100.0μL DMSO. After 5 minutes,
the plates were read on a Multiskan Spectrum (Thermo
Electron Corporation, Marietta, Ohio) at 570nm. Assays
were performed in triplicate on three independent experi-
ments. The concentration of drug exhibited 50% inhibition
of cells (IC50) was calculated using the software of Dose-
Eﬀect Analysis with Microcomputers.
2.5. Real-Time RT-PCR. Real-Time RT-PCR was executed
as in a previous report [10]. Brieﬂy, total RNA was
extracted from sample cells with Trizol. The RNA was
precipitated by isopropyl alcohol and rinsed with 70%
ethanol. Single-strand cDNA was prepared from the puriﬁedJournal of Biomedicine and Biotechnology 3
Table 1: The IC50 values of YQ36 and DOX on three panels of chemosensitive tumor cell line and their chemoresistance subline. The fold
indicated the index of IC50 on chemoresistance subline versus chemosensitive cell line.
Cell lines IC50 (μM)
YQ36 Fold Doxorubicin Fold
KB 5.80 ± 0.39 0.82 4.35 ± 0.16 6.60
KB/VCR 4.78 ± 0.66 28.69 ± 1.87
MCF-7 15.68 ± 1.41 0.50 29.76 ± 1.48 4.49
MCF-7/DOR 7.90 ± 0.73 133.48 ± 13.95
K562 5.64 ± 1.40 2.28 3.06 ± 0.04 4.47
K562/ADR 12.86 ± 1.97 13.68 ± 1.03
RNAusingoligo(dT)priming(ThermoscriptRTkit;Invitro-
gen), followed by SYBR-Green real-time PCR. The primers
are as follows: MDR1, 5 -ctcatcgtttgtctacagttcgt-3 ,a n d
5 -gctttctgtcttgggcttgt-3 ; GAPDH, 5 -gagtcaacggatttggtcgt-
3, 5 -ttgattttggagggatctcg-3 . The threshold cycle for PCR
products was deﬁned as the cycle at which the SYBR-
Green ﬂuorescent signal was 20 standard deviations above
background. Relative quantiﬁcation of gene transcription
wasperformedusingthecomparativeCTmethod(orDDCT,
method available in the user bulletin of ABI Prism 7700
sequence detection system) with GAPDH and β-actin as the
control. Melting dissociation was performed to evaluate the
purity of the PCR product.
2.6. Drug Eﬄux Assay. KB and KB/VCR cell lines were
cultured at 37
◦Ci na5 %C O 2 atmosphere. After treating
with YQ36(10μM) or doxorubicin(10μM) for 3 hours, cells
were washed twice with serum-free media, then incubated in
fresh media plus 10% heat-inactivated newborn calf serum;
cells were harvested at diﬀerent times (0, 15, 30, 45, 60,
120, 180, 240 minutes as indicated in Results) and checked
for ﬂuorescence using a FACSCalibur (Becton Dickinson,
Lincoln Park, NJ). Excitation and emission wavelengths were
488 and 585nm, respectively.
2.7.DNAAgaroseGelElectrophoresis. KB/VCRcells(5 ×105)
were exposed to YQ36 for 48 hours. DNA fragmentation was
extracted as in a previous report [11]. Brieﬂy, harvested cells
were lysed by equal volumes of 1.2% SDS. By adding 7/10
volume of the precipitation solution (3mol/L CsCl, 1mol/L
potassium acetate, 0.67mol/L acetic acid) and spinning for
15 minutes at 14,000g, DNA fragmentation was kept in
the supernatant, which was then absorbed by a miniprep
spin column. Finally, DNA was eluted with 50μLT Eb u ﬀer
(pH, 8.0) and electrophoresed in parallel on the same 1.5%
agarose gel in 1x TAE buﬀer with 0.5mg/mL ethidium
bromide staining to facilitate visualization by ﬂuorescence
under UV light. Images were photographed by Bio-Rad
GD2000 (Bio-Rad, Hercules, CA, USA).
2.8. Mitochondrial Isolation. Harvested cells were washed
with cold PBS and resuspend in 200μL mitochondrial
isolation buﬀer (Mannitol 200mM, Sucrose 70mM, EGTA
1mM, Hepes 10mM, Protease inhibitor cocktail). Homoge-
nize cells on ice with a glass homogenizer. Centrifuge 1000g
at 4◦C for 10 minutes and collect the supernatant. Then Spin
10,000–15,000g for 15 minutes at 4◦C and the pellet was
collected for further experiment.
2.9. Caspase-3/7 Activity and PKC Activity Assay. Cells were
cultured in 96-well plates, and caspase activity was measured
using the luminescent Caspase-Glo 3/7 Assay (Promega,
Madison, WI), following the manufacturer’s protocol at the
indicatedtimepoints.PKCactivityassaywasmeasuredusing
thePepTagNon-RadioactivePKCAssay(Promega,Madison,
WI) following the manufacturers protocol.
2.10. P-gp ATPase Assays. P-gp ATPase assay was conducted
using the Pgp-Glo Assay System (Promega, Madison, WI),
following the manufacturers protocol. The activity of Pgp
ATPase was measured in the presence of variation concen-
tration Na3VO4 and YQ36. The luminescence of the sample
reﬂects the ATP level in the sample, which is negatively
correlated with the activity of Pgp ATPase and was detected
in a Varioskan Flash (Thermo Type3001).
2.11. Western Analysis. Proteins of KB and KB/VCR cell
lines were extracted in immunoprecipitation assay buﬀer
(50.0mMNaCl,50.0mMTris-HCl,1.0%TritonX-100,1.0%
sodium deoxycholate, and 0.1% SDS) and 20.0–100.0μgo f
total protein was loaded per lane. Proteins were fraction-
ated on 8%–15% Tris-Glycine pre-cast gels, transferred to
nitrocellulose membrane (Pierce Biotechnology, Rockford,
IL), and probed with primary antibodies and then HRP-
labeled secondary antibodies. Proteins were visualized using
ECL (Pierce Biotechnology).
2.12. Statistical Analysis. For all parameters measured, the
values for all samples in diﬀerent experimental conditions
were averaged and the SD of the mean was calculated. The
signiﬁcance of diﬀerences between the values of the groups
was determined with unpaired Student’s t-test. Signiﬁcance
levels were set at P<. 05.
3. Results
3.1. Antiproliferation of YQ36 on Sensitive and Multidrug-
Resistance Cells. In order to evaluate the anti-multidrug
resistant eﬀect of YQ36 on tumor cells, antiproliferative
activity of YQ36 was tested using a panel of chemosensitive4 Journal of Biomedicine and Biotechnology
celllinesandtheirchemoresistantsublines,includinghuman
oral squamous carcinoma cell lines (KB and KB/VCR),
human breast cancer cell lines (MCF-7 and MCF-7/DOR)
and human leukemia cell lines (K562 and K562/ADR). All
the six cell lines responded dose dependently to YQ36 and
Doxorubicin (DOX) after 48 hours treatment. The IC50
values (Table 1) showed that, compared with their parental
cells, KB/VCR, MCF-7/DOR, and K562/ADR cells appeared
to be more resistant to DOX (6.60-fold, 4.49-fold, and 4.47-
fold,resp.).Incontrast,YQ36showedparallelcytotoxicityon
KB,MCF-7,andK562cells(IC50 =5.80,15.68,and5.64μM)
andtheircorrespondingMDR-positivesubcells(IC50 =4.78,
7.90, and 12.86μM). The dose-response curves of all six cell
lines were shown in Figure 2. By comparing IC50 values, the
human oral squamous carcinoma cell lines were chosen for
further research. To sum up, YQ36 showed strong cytotoxic
eﬀect on both parental and MDR cell lines, suggesting that
YQ36mighthavepromisinganti-multidrugresistantactivity.
3.2.MDR1WasAmpliﬁedandP-gpWasExpressedinKB/VCR
Cells. To characterize the drug-resistant cells, we used Real-
Time PCR to identify mRNAs which were diﬀerentially
expressed in parental and daughter cell lines. Figure 3(a)
showedthatMDR1wasdramasticallyoverexpressedindrug-
resistant cells and it showed a 104-fold at MDR1 mRNA
level in KB/VCR cells compared with that of KB cells. In
addition,WesternBlottingresultsconﬁrmedP-gpexpression
in KB/VCR cells only (Figure 3(a)). These results suggested
that MDR1 (P-gp expression) is involved in the acquired
resistance as previously reported.
3.3. YQ36 Could Accumulate in KB/VCR Cells. The major
function of P-gp was to increase drug eﬄux, which is one
of the most important mechanisms of MDR to decrease
intracellular drug concentration. In our study, as shown
in Figure 3(b), the amount of YQ36 was not obviously
decreased in KB and KB/VCR cells. However, the amount
of doxorubicin (DOX) was decreased signiﬁcantly in drug-
resistant cells in a time-dependent manner. These results
indicated that YQ36, rather than Dox, was accumulated in P-
gp positive KB/VCR cells, which may contribute to exhibited
equal eﬀect of YQ36 in both parental and MDR cell lines.
3.4. YQ36 Had No Eﬀects on P-gp Expression or Activity.
YQ36 accumulated in KB/VCR cells might be attributed to
the modulation of P-gp function. There are two potential
mechanisms accounting for the decreasing of P-gp function:
ﬁrst, downregulated expression of P-gp; second, inactivate
the function of P-gp. In order to determine whether YQ36
was capable of reducing the expression of P-gp, we detected
P-gp expression in KB/VCR cells treated with 10μMY Q 3 6
for 12, 24, and 48 hours. The results displayed that P-gp level
was not obviously decreased (Figure 3(c)).
There were some evidences indicated that Protein Kinase
C (PKC) could phosphorylate P-gp and might change its
activity [4, 12, 13]. It was also reported that BIM analogues
had strong inhibition on PKC activity. As a BIM analogue,
YQ36 might inactivate P-gp via reduced phosphorylation
by inhibiting PKC. To examine this possibility, we detected
the eﬀect of YQ36 on PKC by Peptag-Assay Kit. According
to the manufacturer’s protocol, the level of phosphorylated
speciﬁc peptide indicated the activity of pan-PKC. As
shown in Figure 3(d), YQ36 failed to decrease the amount
of phosphorylated speciﬁc peptide. However, the positive
control group BIM exhibited inhibition of PKC activity in a
dose-dependent manner. These results indicated that YQ36,
asoneoftheanaloguesofBIM,hadlittleeﬀectontheactivity
of PKC, implying that YQ36 might not be able to inhibit the
phosphorylation of P-gp thus fail to aﬀect the function of P-
gp.
As YQ36 had no eﬀect on P-gp expression or activity,
one more explanation for accumulation of YQ36 in KB/VCR
cells might be that YQ36 did not serve as a substrate for
P-gp, thus escaping from eﬄuxed mediated by P-gp. In
order to verify this hypothesis, Pgp-Glo Assay system was
used to detect whether YQ36 was the substrate for human
recombinationP-gp.TheresultscameoutthatYQ36failedto
disturb the function of ATPase in human recombination P-
gp. In contrast, sodium vanadate exhibited dose-dependent
inhibition on activity of human recombination P-gp in
vitro (Figure 3(e)). To summarize, YQ36 might not be the
substrate for P-gp. These results may explain for the fact that
YQ36 could be accumulated in P-gp positive cells.
3.5. YQ36 Caused Apoptosis in KB/VCR Cells In Vitro. DNA
fragmentation is a common feature of apoptotic cell death.
Electrophoretic analysis of DNA (Figure 4(a)) showed that
exposure of KB/VCR cells to 10μM YQ36 for 12, 24, and 48
hours resulted in a characteristic fragmentation of DNA, a
biochemicalhallmarkofapoptosis,atintranucleosomalsites.
In addition, the result of measuring caspase-3/7 activity also
indicated that YQ36 induced apoptosis in KB/VCR cells in a
time-dependent manner (Figure 4(b)).
Caspase, known as crucial mediators of apoptosis,
depends on proteolytic activation of the procaspase forms
to enzymatically active forms. When KB/VCR cells were
treated with 10μM YQ36 for 12, 24, and 48 hours, the
levels of cleaved caspase3 and Apaf-1 were signiﬁcantly
increased accompanied by the downregulation of both
procaspase-9 and procaspase-3 (Figure 4(c)). In order to
elucidate whether YQ36-driven apoptosis was accompanied
by caspase-independent apoptosis or necrosis, KB/VCR cells
were pretreated with the caspase inhibitor BOC-D-FMK
(100μM) and Z-DEVD-FMK (40μM), respectively, followed
by exposure to 10μM YQ36 for 48 hours. As illustrated in
Figures 5(a) and 5(b), the caspase inhibitor BOC-D-FMK
(100μM) and Z-DEVD-FMK (40μM) signiﬁcantly reversed
YQ36-induced death. Collectively, the main mechanism of
YQ36 cytotoxicity is based on caspase-dependent apoptosis
induction.
There are many proteins related to the mitochondrial
pathway. MAPKs and Bcl-2 family were two major protein
familiesregulatingmitochondriaandcaspase-3pathway.The
expressions of Bcl-2, Bax, JNK, and p-JNK were measured in
KB/VCR cells treated with YQ36 (10μM, 12–48 hours). As
shown in Figure 4(c), YQ36 increased the expression of totalJournal of Biomedicine and Biotechnology 5
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Figure 2: YQ36 inhibited the proliferation on three panels of chemosensitive tumor cells and their chemoresistance subline. (a) Human
oral squamous carcinoma cell lines (KB and KB/VCR) were treated with YQ36 or DOX (0.16–100μM) for 48 hours. Points represent the
mean fractional survival;errorbars representstandard deviation. (b)Human breastcancer cell lines (MCF-7and MCF-7/DOR)were treated
with YQ36 or DOX (0.16–100μM) for 48 hours. Points represent the mean fractional survival; error bars represent standard deviation. (c)
Human leukemia cell lines (K562 and K562/ADR) were treated with YQ36 or DOX (0.32–100μM) for 48 hours. Points represent the mean
fractional survival; error bars represent standard deviation.
and phosphorylated JNK and decreased Bcl-2 expression
in 48 hours. There was, thereby, an increase in Bax/Bcl-2
ratio after YQ36 treatment (Figure 4(f)). In order to further
demonstrate that Bcl-2 family participated in YQ36-induced
apoptosis, we examined the protein expression of Bax from
the mitochondrial fraction. The data suggested that there
was an increased amount of Bax in mitochondrial fraction
(Figure 4(e)).6 Journal of Biomedicine and Biotechnology
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Figure 3: The action of YQ36-induced antimultidrug-resistance on KB/VCR cells.Journal of Biomedicine and Biotechnology 7
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Figure 4:YQ36causedapoptosisinKB/VCRcellsinvitro.(a)YQ36inducedacharacteristicfragmentationofDNAinKB/VCRcells(10μM,
6–24 hours). (b) The result of measuring caspase-3/7 activity indicated YQ36 induced KB/VCR cells apoptosis in time-dependent manner.
The error bars represent standard deviation and ∗∗represent P<. 01 versus control. (c) Caspase activation and mitochondrial pathway
involved in YQ36-induced apoptosis. Cells were treated with YQ36 (10μM) for 6, 12, and 24 hours, and whole-cell lysates were collected and
immunoblottedwithindicated antibodies. (d)Theexpressionsofantiapoptoticproteinsweredecreased inKB/VCRcells(10μMYQ36, 6–24
hours). (e) The protein expression of Bax in mitochondrial fraction after treated with YQ36 (10μM) for 6, 12, and 24 hours, and the HSP60
was used as a housekeeper for mitochondrial fraction. (f) Densitometric analysis of expression of Bcl-2 and Bax relative to the control.
Recent research demonstrated that resistance to
chemotherapeutic drugs was associated with antiapoptotic
proteins upregulation. To explore whether the antiapoptotic
proteins play an important role in YQ36’s anti-multidrug
resistant mechanism in KB/VCR cells, the expressions of Akt,
p-Akt, Smac, and XIAP were measured by using Western
blotting. As shown in Figure 4(d),Y Q 3 6( 1 0μM) obviously
decreased XIAP protein levels (12–48 hours), whereas, the
expression of Smac was not changed obviously, and the
decrease of p-Akt (Ser473) was not reduced until exposure
time prolonged to 48 hours.
3.6. YQ36 Accumulated in Nucleus and Induced DNA Damage
in KB/VCR Cells. Interestingly, YQ36 was a ﬂuorescent com-
pound;sowefurtherinvestigatedthesubcellulardistribution
of YQ36. Fluorescence Microscope was used to observe
the distribution of YQ36 in KB/VCR cells. As shown in
Figure 6(a), YQ36 mainly accumulated in the nucleus (arrow
in Figure 6(a)). This observation encouraged us to further
investigate the action of YQ36 in the nucleus.
Mounting evidences indicated that p53 was a sense
element in DNA damage. To determine whether YQ36
induced DNA damage, p53 and p-p53 (Ser20) were detected8 Journal of Biomedicine and Biotechnology
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Figure 5: YQ36-caused apoptosis was caspase-dependent. (a) The
morphology of KB/VCR cells treated with YQ36 (10μM, 48 hours)
plus with or without caspase inhibitor (100μM BOC-D-FMK and
40μM Z-DEVD-FMK) (100×). (b) The survival rate of KB/VCR
cells treated with YQ36 (10μM, 48 hours) plus with or without
caspase inhibitor (100μM BOC-D-FMK and 40μMZ - D E V D -
FMK).
by Western blotting. As shown in Figure 6(b), the phos-
phorylation level of p53 increased considerably while the
expression of total p53 remained unchanged. These results
suggested that YQ36 induced DNA damage in KB/VCR cells.
4. Discussion
Up to now, the escape of cancer cells from chemotherapy
through activation of MDR mechanisms was a major reason
for systemic cancer treatment failure. Among these, the
eﬀectiveness of many clinical used drugs is limited by the fact
that they are substrates of the eﬄux pumps P-gp (MDR1).
In this study, YQ36 exhibited high anti-multidrugresistant
activity in P-gp-positive cancer cells, causing DNA damage
and ﬁnally induced apoptosis via mitochondrial pathway in
KB/VCR cells.
So far, numerous studies have conﬁrmed that the expres-
sion of P-gp is an adverse prognostic factor for complete
remission and survival in both leukemia and solid tumor
[14, 15]. P-gp, a member of the ABCB subfamily, stands
out among ABC transporters by conferring the strongest
resistance to the widest variety of compounds. Three-
dimensional modeling of human MDR1/P-gp indicates that
these glycoproteins function as eﬃcient ATP-dependent
gate-keepers, which scan the plasma membrane and its inner
leaﬂet to ﬂip lipophilic substrates to the outer membrane
leaﬂet [16]. Several agents with hyperactivity against MDR
cells, as, for example, doxorubicin [17], were P-gp transport
substrates. In our experiment, similar intracellular concen-
trations of YQ36 were observed in KB/VCR cells and KB
cells. In addition, it showed that neither the P-gp protein
level nor the phosphorylation of P-gp was downregulated in
MDR-positive cells. It indicated that YQ36 may not be a P-gp
transport substrate. This hypothesis was further conﬁrmed
by the results that YQ36 failed to modify the function of
ATPase in human recombination P-gp.
Most of studies had described that increased expression
and activity of PKC could be associated with the MDR
phenotype [12, 13]. The importance of PKC-mediated phos-
p h o ry l a t i o no fP - gpi ss t i l lu n c l e a ri na ﬀecting P-gp function.
Some BIM analogues, as the PKC inhibitor, had been
reported to reverse multidrug resistance in MDR-positive
cells [7, 18, 19]. Interestingly, some BIM analogues (such as
Ro 32-2241 and GF 109203X) were the substrates for P-gp
but did not reverse multidrug resistance by inhibiting PKC
phosphorylation of the P-gp to modulate P-gp function [7,
19]. Thus the escape from being substrates for P-gp, rather
than the inhibition of PKC-dependent phosphorylation of
the P-gp, might be the key point of reversing multidrug
resistance. In this study, our ﬁndings suggested that YQ36,
a novel BIM analogue, was not the substrate for P-gp and
exhibited high activity in both parental cells and MDR
cells. It is the ﬁrst time to report that BIM derivates may
be an eﬀective anti-multidrug-resistance compound without
inhibiting the activity of PKC.
It was most likely that the antitumor eﬀect on KB/VCR
cells was based on YQ36-mediated apoptosis. The results of
the electrophoretic analysis of DNA and caspase-3/7 activity
were consistent with our hypothesis. Moreover, Western
blotting results suggested that the YQ36 treatment induced
apoptosis via mitochondrial pathway. Mitochondria play
a pivotal role in the regulation of apoptosis induced by
diverse death stimuli [20–22]. Once transition pores opened
on mitochondria, cytochrome c, the cell death-promoting
factor, released and leads to the formation of a complex
consisting of apoptosis-activating factor 1 (Apaf-1) and
caspase-9 and initiated the proteolytic cascade. Therefore,
the observation of YQ36-mediated activation of procaspase-
9, procaspase-3 suggested that mitochondrial-mediated cas-
pase cascade pathway played a pivotal role in YQ36-induced
apoptosis. Furthermore, YQ36-induced downregulation of
XIAP, one of the inhibitors of apoptosis proteins (IAPs) fam-
ily [23, 24], was detected in KB/VCR cells. Since XIAP was
able to inhibit activation of caspase-3 to protect cells from
apoptosis, downregulation of XIAP provided an additionalJournal of Biomedicine and Biotechnology 9
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Figure 6: YQ36-mediated DNA damage in KB/VCR cells. (a) The YQ36 accumulated in nucleus was detected by ﬂuorescent microscope
and the arrow indicated that YQ36 accumulated in nucleus. (b) Upregulated p-p53 was detected in YQ36-induced DNA damage by Western
Blotting.
indication that YQ36-exerted antitumor eﬀect was related to
the activation of caspase cascade.
There are two major pathways involved in mitochondria-
mediated apoptosis. Through convergence of the signaling
at the mitochondrial membrane, Bcl-2 family [25, 26]c a n
inﬂuencethemitochondriadirectly.TheBcl-2proteinfamily
includes proapoptotic members, such as Bcl-2, Bcl-xL, and
Bcl-W and antiapoptotic members like Bax. Antiapoptotic
proteins act as repressors of apoptosis by blocking the
release of cytochrome c, whereas proapoptotic members
act as promoters. The overall action was dependent on
the balance between Bcl-2 [27, 28]a n dB a x[ 29], and
the increase ratio of Bax/Bcl-2 was associated with the
release of cytochrome c [30]. Our results demonstrated
a dramatic increase of Bax/Bcl-2 ratio in KB/VCR cells
treated with YQ36, indicating that the regulation of Bcl-2
family expression plays an important role in YQ36-induced
apoptosis. It is reported that JNK can inﬂuence the binding
ability of Bcl-2 with Bax and impair antiapoptotic function
of Bcl-2 by phosphorylation [31, 32]. In present study, our
results exhibited that YQ36 obviously upregulated both the
total expression of JNK and its phosphorylated status. These
observations suggested that the MAPK’s activity may be also
involved in the YQ36-mediated apoptotic process.
Recent investigations had demonstrated that the coor-
dinated overexpression of the diﬀerent IAPs may aﬀect the
tumor cell resistance to drug-induced apoptosis [33]. The
IAPsarearecentlyidentiﬁedgroupofantiapoptoticproteins,
including XIAP, AKT, and others. XIAP expression had been
demonstrated to be associated with a shorter duration of
remission and overall survival in acute myeloid leukemia
[34]. In contrast, Smac/Diablo is a mitochondrial protein
that functions as a regulatory component during apoptosis
[35, 36]. The interaction of Smac/Diablo with XIAP could
relieve the inhibitory eﬀect of IAPs on caspase [35, 36].
Our results showed that YQ36 obviously downregulated
the expression of XIAP but failed in changing the level
of Smac/Diablo, indicating that the regulation of XIAP
expression might play an important role in YQ36-induced
apoptosis in KB/VCR cells.
The major function of tumor suppressor protein p53
is to respond to DNA damage. The phosphorylated p53
promoted activation of p53 in response to DNA damage [9,
37]. In our study, YQ36-caused DNA damage was conﬁrmed
by detected upregulation of p-p53 (Ser20) before changing
the expression of downstream proteins (such as JNK, Bcl-
2, caspase). Moreover, recent research demonstrates that
p53, as a transcriptional factor, mediates the upregulation
of Bax after its activation. However, our result showed the
whole protein expression of Bax was rarely changed. It
might implicated that it was the MAPK signaling rather
than the p53 signaling regulating the Bcl-2 family protein
function. Collectively, these results indicated that YQ-36-
elicted apoptosis of KB/VCR cells was primarily caused by
DNA damage. Although we failed to distinguish the type
of DNA damage, according to our data, YQ36-caused DNA
damage might not be generated from the DNA cross-link or
double strand breaks mediated by topo II (data not shown).
Further experiments were still undergoing to reveal the exact
style of YQ36-induced DNA damage.
5. Conclusions
Taken together, our experiments demonstrated that YQ36
was a potent agent against MDR cells and DNA damage
together with mitochondrial pathway might be involved in
signaling YQ36-induced apoptosis.
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